A fluorinated benzhydrylpiperazine building block
Used as a synthesis intermediate for APIs in medicinal chemistry
| |
1-Bis(4-fluorophenyl)methyl piperazine (CAS number 27469-60-9), also referred to as difluorobenzhydrylpiperazine, has a piperazine connecting to a diphenylmethane with two fluorine atoms at para-positions. 1-Bis(4-fluorophenyl)methyl piperazine appears in synthesis of drugs such as flunarizine and lomerizine. The diphenylpiperazine drugs are typically classified as calcium antagonists (calcium channel blockers) and used clinically for the treatment of migraines. The synthesis involves a one-step reaction of 1-bis(4-fluorophenyl)methyl piperazine with the halogenated analogues of the second fragments via nucleophilic substitution.
1-Bis(4-fluorophenyl)methyl piperazine also involves in synthesis of piperazinylacetamides for anticancer drugs, with half maxima growth inhibitory concentration (GI50) of 4.36 µM.
Multiple functional groups
For facile synthesis
Fluorinated benzhydrylpiperazine building block
For drug discovery, medicinal chemistry and biochemistry research
Worldwide shipping
Quick and reliable shipping
High purity
>98% High purity
General Information
| CAS Number | 27469-60-9 |
| Chemical Formula | C17H18F2N2 |
| Full Name | 1-Bis(4-fluorophenyl)methyl piperazine |
| Molecular Weight | 288.34 g/mol |
| Synonyms | 1-(4,4'-Difluorobenzhydryl)piperazine, 1-(4,4'-Difluorodiphenylmethyl)piperazine, 4,4'-Difluorobenzhydrylpiperazine |
| Classification / Family | Fluorinated building block, Heterocyclic building block, APIs, antimicrobials |
Chemical Structure
Product Details
| Purity | 98% |
| Melting Point | Tm = 88 °C – 92 °C |
| Appearance | White powder |
MSDS Documentation
Literature and Reviews
- (4-(Bis(4-Fluorophenyl)methyl)piperazin-1-yl)(cyclohexyl) methanone hydrochloride (LDK1229): a new cannabinoid CB1 receptor inverse agonist from the class of benzhydryl piperazine analogs, M. Mahmoud et al., Mol. Pharmacol., 87, 197–206(2015); DOI: 10.1124/mol.114.095471.
- Mechanistic modelling of monoglyceride lipase covalent modification elucidates the role of leaving group expulsion and discriminations inhibitors with high and low potency, F. Galvani et al., J. Chem. Inf. Model., 62, 2771–2787(2022); DOI: 10.1021/acs.jcim.2c00140.
- Synthesis and biological evaluation of novel benzhydrylpiperazine-coupled nitrobenzenesulfonamide hybrids, V. Murthy et al., ACS Omega 2021, 6, 9731–9740; DOI: 10.1021/acsomega.1c00369.
